Protalix BioTherapeutics, Inc. (PLX) Institutional Ownership

Ownership Summary

Protalix BioTherapeutics, Inc. (NYSE:PLX) currently has 16 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The percentage of Protalix BioTherapeutics owned by institutions changed from 18.0% in September 2025 to 1.9% in December 2025, marking a slight down trend.
• In percentage terms, this reflects as a holdings change of 25.63% quarter on quarter, and a decrease of 65.96% year over year.
• A review of institutional activity for Protalix BioTherapeutics shows 8 of 16 filers increasing their positions, while 2 reduced their stake, and 6 remained unchanged.
• This class of investors increased its holdings in Protalix BioTherapeutics to 1.50Mn shares for the 13F-cycle ending December 2025, up by 305.18K shares quarter on quarter, and down 2.97Mn shares year over year.
• With 500.00K shares, Stratos Wealth Partners, LTD. commands the largest institutional position in Protalix BioTherapeutics as of December 31, 2025, equating to 0.65% of the company.
• Among the most significant buyers of Protalix BioTherapeutics during December 2025 were Round Rock Advisors LLC (155.10K), UBS Group AG (72.24K), VANGUARD GROUP INC (24.13K), State of Alaska, Department of Revenue (21.83K), SG Americas Securities, LLC (17.16K).
• Leading sellers of Protalix BioTherapeutics stock in December 2025 included SBI Securities Co., Ltd. (200), AMALGAMATED BANK (112).
• The top 10 institutional holders of Protalix BioTherapeutics for the quarter ending December 2025 included Stratos Wealth Partners, LTD. (500.00K), VANGUARD GROUP INC (488.55K), UBS Group AG (262.52K), Round Rock Advisors LLC (155.10K), EARNED WEALTH ADVISORS, LLC (25.98K), State of Alaska, Department of Revenue (21.83K), SG Americas Securities, LLC (17.16K), R Squared Ltd (14.63K), TD Waterhouse Canada Inc. (6.00K), AMALGAMATED BANK (2.27K).